Jorg Engelbergs PhD

Dr. Jorg Engelbergs is currently working for the Paul-Ehrlich-Institut (PEI) in Langen, Germany, as a regulatory-scientific expert and assessor for biopharmaceuticals, especially Biotechs (Monoclonal Antibodies with a focus on Quality CMC, Non-Clinic, Biomarker Companion Diagnostics Personalized Medicines. He is involved in the scientific assessments of GCP conformity of clinical phase I-III drug trials and the European process of market authorization of biopharmaceuticals, comprising scientific assessments and national EMA advice.

Dr. Engelbergs is a member of the Pharmacogenomics Working Party (PGWP) at the European Medicines Agency (EMA) and a member of the newly established Heads of Medicines Agencies (HMA) CTFG Sub Group on IVD-CDx. He holds a Diploma in biology and a Ph.D. in cell biology cancer research biotechnology. Before he joined the PEI, he has gained large experience in experimental neuropharmacology and cancer research. At this time he was the last head of the Neuropharmacology laboratory and in the parallel head of the clinical core Genotyping service center SNP, mutation and expression profiling both at the Department of Neurology at the University of Essen Medical School, Germany.